NRx Pharmaceuticals’ NRX-101 Receives FDA Fast Track Designation: A Potential Gamechanger for Treating Complex UTIs
RADNOR, PA — In a significant development that could revolutionize the treatment of complicated urinary tract infections (cUTI) and pyelonephritis, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received Qualified Infectious Disease …
NRx Pharmaceuticals’ NRX-101 Receives FDA Fast Track Designation: A Potential Gamechanger for Treating Complex UTIs Read More